Persones / Equip Humà

Jaume Mora Graupera

Buscador de publicacions

Publicacions

  • Fernandez AF, Assenov Y, Martin-Subero JI, Balint B, Siebert R, Taniguchi H, Yamamoto H, Hidalgo M, Tan AC, Galm O, Ferrer I, Sanchez-Cespedes M, Villanueva A, Carmona J, Sanchez-Mut JV, Berdasco M, Moreno V, Capella G, DAVID NICHOLAS MONK, Ballestar E, Ropero S, Martinez R, Sanchez-Carbayo M, Prosper F, Agirre X, Fraga MF, Graña O, Perez-Jurado L, Mora J, Puig S, Prat J, Badimon L, Puca AA, Meltzer SJ, Lengauer T, Bridgewater J, Bock C and Esteller M.

    A DNA methylation fingerprint of 1628 human samples

    GENOME RESEARCH . 22(2): 407-419. Nº de cites: 331

    [doi:10.1101/gr.119867.110]

  • Mora J.

    Avenços i controvèrsies en el tractament del neuroblastoma d’alt risc

    Pediatría Catalana . 71: 62-69.

  • Acosta S, Mayol G, Rodriguez E, Lavarino C, de Preter K, Kumps C, Garcia I, de Torres C and Mora J.

    Identification of tumoral glial precursor cells in neuroblastoma

    CANCER LETTERS . 312(1): 73-81. Nº de cites: 12

    [doi:10.1016/j.canlet.2011.08.004]

  • Conde N, Cruz-Martínez O, Albert A and Mora J.

    Antiangiogenic Treatment as a Pre-Operative Management of Alveolar Soft-Part Sarcoma

    PEDIATRIC BLOOD & CANCER . 57(6): 1071-1073. Nº de cites: 16

    [doi:10.1002/pbc.23241]

  • Mora J, de Torres C, Parareda A, Torner-Rubies F, Galván P, Rodriguez E, Cardesa-Salzmann TM, Salvador-Hernandez H, Suñol M, Huguet R and Cruz-Martínez O.

    Treatment of Ewing Sarcoma Family of Tumors With a Modified P6 Protocol in Children and Adolescents

    PEDIATRIC BLOOD & CANCER . 57(1): 69-75. Nº de cites: 12

    [doi:10.1002/pbc.22813]

  • Mora J.

    ¿Por qué la quimioterapia no cura a todos los pacientes con cáncer?

    Anales de Pediatría Continuada . 9(3): 191-196.

  • Garcia I, Mayol G, Rodriguez E, Suñol M, Gershon TR, Ríos J, Cheung NK, Kieran MW, George RE, Perez-Atayde AR, Casalà C, Galván P, de Torres C, Mora J and Lavarino C.

    Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma

    MOLECULAR CANCER . 9: 277-277. Nº de cites: 58

    [doi:10.1186/1476-4598-9-277]

  • Royer-Pokora B, Busch M, Beier M, Duhme C, de Torres C, Mora J, Brandt A and Royer HD.

    Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm

    HUMAN MOLECULAR GENETICS . 19(9): 1651-1668. Nº de cites: 61

    [doi:10.1093/hmg/ddq042]

  • De Preter K, Vermeulen J, Brors B, Delattre O, Eggert A, Fischer M, Janoueix-Lerosey I, Lavarino C, Maris JM, Mora J, Nakagawara A, Oberthuer A, Ohira M, Schleiermacher G, Schramm A, Schulte JH, Wang Q, Westermann F, Speleman F and Vandesompele J.

    Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature

    CLINICAL CANCER RESEARCH . 16(5): 1532-1541. Nº de cites: 76

    [doi:10.1158/1078-0432.CCR-09-2607]

  • Roche A, Mora J, Perez Mdel M, Gean Molins E, Pérez-Dueñas B, O'Callaghan-Gordo M, Catala J, de Torres C, Cruz-Martínez O, Prat-Bartomeu J and Parareda A.

    Axenfeld-Rieger Ocular Anomaly and Retinoblastoma Caused by Constitutional Chromosome 13q Deletion

    PEDIATRIC BLOOD & CANCER . 54(3): 480-482. Nº de cites: 3

    [doi:10.1002/pbc.22354]